← Leaderboards
Anne-Marie Carbonell
Oncosynergy, Inc.
$500,000
Attributed
$1,000,000
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $756K · FY2019–20$1M$750K$500K$250K$0
'19
'20
Funding mix
By agency
NIH$1,000,000 · 2
By mechanism
R41$1,000,000 · 2
Top collaborators
- Todd Justen Kilbaugh3 shared
- Balveen Kaur1 shared
Others in their field
Other Emerging Leaders on “Recurrence”
- Manish Ishwar Shah · Baylor College Of Medicine$13,280,421
- Kevin Navin Sheth · Brigham And Women'S Hospital$10,362,027
- Dale Sandler · Social And Scientific Systems, Inc.$9,632,923
- Zhiyong Yang · Fzata, Inc.$7,816,062
- Kathleen Nicol · Research Inst Nationwide Children'S Hosp$7,152,405
- Phillip W Graham · Research Triangle Institute$7,075,871
Research focus
RecurrenceFda ApprovedIntegrinsPatternBrainGlioblastomaCytokineImmuneMediatingOperative Surgical ProceduresSmall Business Technology Transfer ResearchMonoclonal AntibodiesIn VivoIn VitroChemosensitizationClinical TrialsAnimal EfficacyAntidepressive AgentsActigraphyAnticonvulsantsAnticoagulantsAmericanCellular AssayCentral Nervous System Injury
Grant awards (4)
Novel monoclonal antibody for single dose treatment of acute CNS injury$200,000
R41 · FY2020 · NS · contact PI
Novel monoclonal antibody for single dose treatment of acute CNS injury$43,953
R41 · FY2020 · NS · contact PI
Novel monoclonal antibody for single dose treatment of acute CNS injury$456,047
R41 · FY2019 · NS · contact PI
Oncolytic virus-mediated target delivery of a therapeutic antibody fragment in glioblastoma$300,000
R41 · FY2019 · CA · contact PI